Longitudinal Changes in Insulin Resistance Indices During SGLT2 Inhibitor Therapy in Type 2 Diabetes: A Prospective Single-Arm Cohort Study
Preprint
- 28 August 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce cardiorenal events, but their association with insulin resistance in routine care is incompletely characterised, particularly where medication records cannot exclude exogenous insulin use. In this prospective, single-arm, single-centre cohort study, 54 adults with type 2 diabetes initiating an SGLT2 inhibitor were assessed at baseline, 3 and 6 months. Outcomes were HOMA-IR and the insulin-independent triglyceride–glucose (TyG) index within a family of 15 metabolic and laboratory variables, tested by Wilcoxon signed-rank test with Benjamini–Hochberg control and summarised as the rank-biserial correlation. Median HOMA-IR fell from 8.38 (IQR 3.47–13.26) to 3.14 (2.19–4.39), −62.6% (r = −0.79, adjusted p < 0.001), and the TyG index from 9.45 to 9.04 (−4.3%, r = −0.63, adjusted p < 0.001). Haemoglobin rose 5.0%, consistent with plasma-volume contraction. Change in HOMA-IR did not track change in HbA1c (ρ = −0.15, p = 0.27). An exploratory kidney-disease × time interaction was nominally significant for TyG (β = +0.31, p = 0.040) but not log-HOMA-IR (β = +0.39, p = 0.077). Because the design was single-arm and confounders unrecorded, these are associations observed during therapy, not treatment effects. The divergence between insulin-dependent and insulin-independent indices is relevant to endpoint selection in controlled studies.Keywords
All Related Versions
This publication has 60 references indexed in Scilit:
- The effects of SGLT2 inhibitors and GLP-1 receptor agonists on the triglyceride to HDL cholesterol ratio and the triglyceride-glucose index in patients with type 2 diabetesJournal of Diabetes and its Complications, 2025
- Triglyceride glucose (TyG) index: A promising biomarker for diagnosis and treatment of different diseasesEuropean Journal of Internal Medicine, 2024
- Effects of dapagliflozin monotherapy and combined aerobic exercise on skeletal muscle mitochondrial quality control and insulin resistance in type 2 diabetes mellitus ratsBiomedicine & Pharmacotherapy, 2023
- Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?Journal Of Nephrology, 2022
- Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 DiabetesDiabetes Therapy, 2019
- Kidney cachexia or protein‐energy wasting in chronic kidney disease: facts and numbersJournal of Cachexia, Sarcopenia and Muscle, 2019
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial EnergeticsJACC, 2019
- SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic HeartJACC: Basic To Translational Science, 2019
- Emerging Role of SGLT-2 Inhibitors for the Treatment of ObesityDrugs, 2019
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985